Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 4 Resectable Pancreatic Cancer 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1 Advanced Pancreatic Cancer 1 Adenocarcinoma 1

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 14 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 8 Irinotecan 8 Trastuzumab 7 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Erlotinib Hydrochloride 5 Sunitinib 4 Ramucirumab 4 Metformin 4 Gefitinib 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Panitumumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × paricalcitol × Clear all

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

34 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡